Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease
Hirsh, Andrew J, Zhang, Jim, Zamurs, Andra, Fleegle, Jacquelyn, Thelin, William R, Caldwell, Ray A, Sabater, Juan R, Abraham, William M, Donowitz, Mark, Cha, Boyoung, Johnson, Kevin B, St George, Judith A, Johnson, M Ross, Boucher, Richard C
Published in The Journal of pharmacology and experimental therapeutics (01.04.2008)
Published in The Journal of pharmacology and experimental therapeutics (01.04.2008)
Get full text
Journal Article
Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-Nâ²-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
Andrew J. Hirsh, Jim Zhang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Ray A. Caldwell, Juan R. Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, Judith A. St. George, M. Ross Johnson, Richard C. Boucher
Published in The Journal of pharmacology and experimental therapeutics (01.04.2008)
Published in The Journal of pharmacology and experimental therapeutics (01.04.2008)
Get full text
Journal Article